Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This clinical trial aims to evaluate the efficacy and safety of Becotatug Vedotin (EGFR-ADC) in combination with Pucotenlimab(Anti-PD-1 Monoclonal Antibody) as neoadjuvant therapy for patients with Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma. The primary objective is the pathological complete response(pCR)rate following neoadjuvant therapy. The secondary objective includes the major pathological response(MPR)rate following neoadjuvant therapy, the objective response rate (ORR), Organ preservation rate, Surgery postponement rate, event-free survival (EFS), overall survival(OS), and safety.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek minimum 18 lat
- •Potwierdzony rak płaskokomórkowy gardła dolnego
- •Możliwość operacyjnego usunięcia nowotworu, stadium III lub IV bez przerzutów
- •Mierzalne ognisko nowotworu
- •Brak wcześniejszego leczenia tego raka
- •Dobry ogólny stan zdrowia (ECOG 0-1)
- •Oczekiwana długość życia co najmniej 3 miesiące
- •Zgoda na antykoncepcję (dla kobiet w wieku rozrodczym)
✗ Disqualifies
- •Przerzuty nowotworu do odległych narządów
- •Niekontrolowana poważna choroba przewlekła
- •Alergia na przeciwciała monoklonalne
- •Poważne problemy z sercem
- •Ciężka infekcja w ostatnie 4 tygodnie
- •Gorączka powyżej 38,5°C przed badaniem
- •Aktywna choroba autoimmunologiczna
- •Historia transplantacji organów lub szpiku kostnego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin 300000
Tianjin, China
Trial contact
Xudong Wang
Hongling Wang
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.